Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis

J Antimicrob Chemother. 2004 Oct;54(4):761-6. doi: 10.1093/jac/dkh411. Epub 2004 Aug 25.

Abstract

Objectives: This study was carried out to explore lectin-functionalized poly (lactide-co-glycolide) nanoparticles (PLG-NPs) as bioadhesive drug carriers against tuberculosis (TB), in order to reduce the drug dosage frequency of antitubercular drugs and thus improve patient compliance in TB chemotherapy.

Methods: Wheat germ agglutinin (WGA)-coated PLG-NPs were prepared by a two-step carbodiimide procedure. This formulation was administered to guinea pigs through the oral/aerosol route for a detailed pharmacokinetic and chemotherapeutic evaluation. Immunological or hepatotoxic effects of WGA lectin, if any, were also determined.

Results: WGA-functionalized PLG-NPs were in the size range of 350-400 nm, with binding of 3-3.5 microg of WGA/mg of PLG-NPs and drug encapsulation efficiency of 54%-66%. Upon administration of lectin-coated PLG-NPs through the oral/aerosol route, the presence of drugs in plasma was observed for 6-7 days for rifampicin and 13-14 days for isoniazid and pyrazinamide. However, upon administration of uncoated PLG-NPs (oral/aerosolized) rifampicin was detectable in plasma for 4-6 days, whereas isoniazid and pyrazinamide were detectable for 8-9 days. All three drugs were present in lungs, liver and spleen for 15 days. Administration of WGA-coated PLG-NPs caused a significant (P < 0.001) increase in the relative bioavailability of antitubercular drugs. Chemotherapeutic studies revealed that three doses of oral/nebulized lectin-coated nanoparticles fortnightly could yield undetectable mycobacterial colony forming units (cfu); this was achievable with 45 doses of oral free drugs.

Conclusion: WGA-functionalized PLG-NPs could be potential drug carriers for antitubercular drugs through the oral as well as aerosol route for effective TB control.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Aerosols
  • Animals
  • Antitubercular Agents* / administration & dosage
  • Antitubercular Agents* / pharmacokinetics
  • Antitubercular Agents* / therapeutic use
  • Biological Availability
  • Colony Count, Microbial
  • Delayed-Action Preparations / administration & dosage
  • Delayed-Action Preparations / pharmacokinetics
  • Delayed-Action Preparations / therapeutic use
  • Disease Models, Animal
  • Drug Carriers / chemistry
  • Female
  • Guinea Pigs
  • Liver / drug effects
  • Liver / metabolism
  • Lung / drug effects
  • Lung / metabolism
  • Lung / microbiology
  • Male
  • Mycobacterium tuberculosis / drug effects*
  • Mycobacterium tuberculosis / isolation & purification
  • Nanotechnology
  • Polyglactin 910 / chemistry*
  • Spleen / drug effects
  • Spleen / metabolism
  • Spleen / microbiology
  • Tissue Distribution
  • Tuberculosis / drug therapy*
  • Tuberculosis / metabolism
  • Wheat Germ Agglutinins / chemistry*

Substances

  • Aerosols
  • Antitubercular Agents
  • Delayed-Action Preparations
  • Drug Carriers
  • Wheat Germ Agglutinins
  • Polyglactin 910